Tyers Asset Management LLC Increases Stock Position in SAGE Therapeutics Inc (NASDAQ:SAGE)

Tyers Asset Management LLC increased its position in SAGE Therapeutics Inc (NASDAQ:SAGE) by 4.6% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,164 shares of the biopharmaceutical company’s stock after purchasing an additional 140 shares during the quarter. Tyers Asset Management LLC’s holdings in SAGE Therapeutics were worth $579,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently made changes to their positions in SAGE. Jennison Associates LLC raised its holdings in shares of SAGE Therapeutics by 163.0% during the first quarter. Jennison Associates LLC now owns 2,355,614 shares of the biopharmaceutical company’s stock worth $374,660,000 after purchasing an additional 1,459,950 shares during the period. FMR LLC lifted its position in shares of SAGE Therapeutics by 8.2% in the first quarter. FMR LLC now owns 7,608,239 shares of the biopharmaceutical company’s stock worth $1,210,091,000 after purchasing an additional 575,163 shares in the last quarter. TimesSquare Capital Management LLC purchased a new stake in shares of SAGE Therapeutics in the first quarter worth approximately $78,762,000. Artisan Partners Limited Partnership lifted its position in shares of SAGE Therapeutics by 124.5% in the first quarter. Artisan Partners Limited Partnership now owns 562,278 shares of the biopharmaceutical company’s stock worth $89,430,000 after purchasing an additional 311,847 shares in the last quarter. Finally, Frontier Capital Management Co. LLC purchased a new stake in shares of SAGE Therapeutics in the first quarter worth approximately $41,174,000.

In related news, Director James M. Frates sold 8,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $160.58, for a total transaction of $1,284,640.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 4.60% of the stock is currently owned by company insiders.



SAGE has been the subject of a number of research analyst reports. William Blair reissued a “buy” rating on shares of SAGE Therapeutics in a research report on Wednesday, July 24th. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of SAGE Therapeutics in a research report on Wednesday, July 24th. BidaskClub lowered shares of SAGE Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday. Oppenheimer cut their price objective on shares of SAGE Therapeutics from $200.00 to $190.00 and set an “outperform” rating on the stock in a research report on Wednesday, August 7th. Finally, Wedbush assumed coverage on shares of SAGE Therapeutics in a research report on Wednesday, May 22nd. They set an “outperform” rating and a $207.00 price objective on the stock. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and thirteen have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $200.27.

SAGE traded down $0.77 during midday trading on Friday, hitting $160.13. 9,619 shares of the company’s stock traded hands, compared to its average volume of 360,666. The company has a market cap of $7.84 billion, a PE ratio of -19.92 and a beta of 2.55. The stock’s fifty day simple moving average is $164.49 and its 200-day simple moving average is $168.11. The company has a debt-to-equity ratio of 0.03, a current ratio of 16.00 and a quick ratio of 16.00. SAGE Therapeutics Inc has a one year low of $79.88 and a one year high of $193.56.

SAGE Therapeutics (NASDAQ:SAGE) last issued its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($3.28) earnings per share for the quarter, beating the consensus estimate of ($3.32) by $0.04. The business had revenue of $0.87 million for the quarter, compared to the consensus estimate of $0.27 million. SAGE Therapeutics’s revenue was down 99.0% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.36) EPS. On average, research analysts expect that SAGE Therapeutics Inc will post -13.32 EPS for the current year.

SAGE Therapeutics Profile

Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone that has completed Phase III clinical trials for the treatment of postpartum depression (PPD).

Featured Article: Why is the LIBOR significant?

Want to see what other hedge funds are holding SAGE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SAGE Therapeutics Inc (NASDAQ:SAGE).

Institutional Ownership by Quarter for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.